InsiderTrades

Form 4 for BLFS BIOLIFE SOLUTIONS INC

Accepted 2022-04-13 00:00:00 ET · period of report 2022-04-12 · accession 0001437749-22-008916 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2022-04-13 2022-04-12 BLFS Foster Karen A. Chief Quality Off M - OptEx — +38.8K 124.0K +46% —
D 2022-04-13 2022-04-12 BLFS Foster Karen A. Chief Quality Off M - OptEx $0.00 -38.8K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-04-12 M A 38,836 — 123,951 D — — (F1) The restricted stock was granted pursuant to BioLife Solutions 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
2 Derivative Restricted Stock Award 2022-04-12 M D 38,836 $0.00 0 D $0.00 · — to — 38,836 Common Stock (F1) The restricted stock was granted pursuant to BioLife Solutions 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).